Axsome Therapeutics, Inc.

AXSM

US05464T1043

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
71.71 ^USD	+0.27%		+5.61%	-9.90%

12:21pm	Morgan Stanley Upgrades Axsome Therapeutics to Overweight From Equalweight, Raises Price Target to $115 From $90	MT
Apr. 02	Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing	MT

Axsome Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 20, 2024 at 07:06 am EST

Axsome Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 270.6 million compared to USD 50.04 million a year ago. Net loss was USD 239.24 million compared to USD 187.13 million a year ago.

Basic loss per share from continuing operations was USD 5.27 compared to USD 4.6 a year ago.

Latest news about Axsome Therapeutics, Inc.

Morgan Stanley Upgrades Axsome Therapeutics to Overweight From Equalweight, Raises Price Target to $115 From $90	06:21am	MT
Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing	Apr. 02	MT
Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	Apr. 01	CI
Mizuho Securities Ups Price Target on Axsome Therapeutics to $109 From $108, Keeps Buy Rating	Mar. 28	MT
HC Wainwright Adjusts Axsome Therapeutics' Price Target to $190 From $180, Keeps Buy Rating	Mar. 26	MT
Citigroup Adjusts Price Target on Axsome Therapeutics to $127 From $125, Maintains Buy Rating	Mar. 26	MT
RBC Lifts Price Target on Axsome Therapeutics to $128 From $123, Says AXS-12 Reaching Primary Endpoint 'Should Enable Approval,' Keeps Outperform Rating	Mar. 26	MT
Axsome Therapeutics Says Survey Shows Narcolepsy Symptoms Persist Despite Treatment	Mar. 25	MT
Transcript : Axsome Therapeutics, Inc. - Special Call	Mar. 25
Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	Mar. 25	CI
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial	Mar. 25	RE
Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in the SYMPHony Phase 3 Trial in Narcolepsy	Mar. 25	CI
Baird Initiates Axsome Therapeutics With Outperform Rating, Price Target is $108	Mar. 19	MT
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	Mar. 19	CI
Axsome Therapeutics Insider Sold Shares Worth $2,257,449, According to a Recent SEC Filing	Mar. 18	MT
Mizuho Cuts PT on Axsome Therapeutics to $108 From $112 After Release of AD Agitation Study Data Faces Delays, Keeps Buy Rating	Feb. 26	MT
UBS Adjusts Axsome Therapeutics Price Target to $107 From $111, Maintains Buy Rating	Feb. 21	MT
RBC Trims Price Target on Axsome Therapeutics to $123 From $126, Notes 'Disappointing' Delay in Data From ADVANCE-2 Trial; Outperform Kept	Feb. 21	MT
Sector Update: Health Care Stocks Lower Late Afternoon	Feb. 20	MT
Sector Update: Health Care Stocks Softer Tuesday Afternoon	Feb. 20	MT
Axsome Therapeutics Q4 Net Loss Widens, Revenue Rises; Shares Drop	Feb. 20	MT
Transcript : Axsome Therapeutics, Inc., Q4 2023 Earnings Call, Feb 20, 2024	Feb. 20
Axsome Therapeutics Q4 Net Loss Widens, Revenue Rises	Feb. 20	MT
Earnings Flash (AXSM) AXSOME THERAPEUTICS Reports Q4 Revenue $71.5M, vs. Street Est of $69M	Feb. 20	MT
Axsome Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI

Chart Axsome Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Axsome Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

71.71 USD

Average target price

121.1 USD

Spread / Average Target

+68.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
AXSOME THERAPEUTICS, INC.	-9.90%	3.41B
CSL LIMITED	-4.06%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+56.15%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.71B

Biopharmaceuticals